Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.
Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.
复制标题
DOI：
10.1002/ccr3.911
复制
发表时间：
2017-05
影响因子：
0.7
通讯作者：
Yamasaki O
中科院分区：
文献类型：
--
作者：
Matsuo T;Yamasaki O
1例转移性皮肤恶性黑色素瘤患者在注射两次纳武单抗（抗PD-1抗体）后发生了沃格特-小柳-原田病样后葡萄膜炎。沃格特-小柳-原田病以针对脉络膜黑素细胞的自身免疫为背景，表明纳武单抗通过瓦解T细胞针对黑素细胞和正常黑素细胞之间共有的共同表位的抑制回路而起作用。
A patient with metastatic cutaneous malignant melanoma developed Vogt‐Koyanagi‐Harada disease‐like posterior uveitis after two nivolumab (anti‐PD‐1 antibody) injections. Vogt‐Koyanagi‐Harada disease, with the background of autoimmunity against choroidal melanocytes, suggests nivolumab be working by disintegrating inhibition circuit of T cells against a common epitope shared between melanoma cells and normal melanocytes.